CD3-Binding Polypeptides for Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CD3-binding molecules suffer from thermal instability, manufacturability issues, and adverse side effects such as cytokine release, limiting their clinical use in treating autoimmune diseases and cancers.
Innovation Solution
Development of CD3-binding domains and polypeptides with improved thermal stability, reduced cytokine release, and enhanced manufacturability, featuring specific amino acid sequences and structural modifications, including humanized immunoglobulin variable regions and linkers, to enhance stability and reduce adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-CD3 antibodies are used to target T-cells for treatment of autoimmune diseases and cancer, then T-cell cytotoxicity and activation are induced, but serious side effects occur including cytokine release and flu-like syndrome
Solution Approach 1:
The patent applies local quality by creating multispecific polypeptides with distinct binding domains: one domain specifically targets CD3 on T-cells to induce cytotoxicity, while another domain targets tumor-associated antigens for selective redirection. This localized functional differentiation allows the therapeutic to activate T-cells against tumor cells while minimizing non-specific cytokine release and systemic side effects
Solution Approach 2:
The patent uses tumor-associated antigens as intermediaries to mediate the interaction between T-cells and tumor cells. The multispecific polypeptide binds both CD3 on T-cells and tumor antigens, using the tumor antigen as a mediator to redirect T-cell cytotoxicity specifically toward tumor cells rather than causing non-specific T-cell activation and cytokine storm
2Reliability
If CD3-binding molecules are developed for therapeutic use, then T-cell activation is achieved, but thermal instability and manufacturability issues limit clinical application
Solution Approach 1:
The patent applies parameter changes by optimizing the amino acid sequences of the binding domains through humanization and engineering modifications. These sequence changes improve the thermal stability and structural integrity of the polypeptides while maintaining their binding affinity for CD3 and tumor antigens, thereby enabling clinical application
3Adaptability or versatility
If multispecific polypeptides are designed to bind both T-cells and tumor cells, then redirected T-cell cytotoxicity is achieved, but structural complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the multispecific polypeptide into distinct functional modules: a CD3-binding domain (such as scFv or Fab fragment) and a tumor antigen-binding domain. These segmented domains are connected by flexible linkers, allowing each domain to independently perform its binding function while simplifying the overall structural design and manufacturing process
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure relates to protein molecules that specifically bind to CD3, which may have at least one humanized CD3-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD3 may have a second binding domain that binds to another target. In one embodiment, multispecific polypeptide molecules bind both tumor antigen-expressing cells and the CD3 subunit of a T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD3-binding poypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.